| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8784878 | ELI LILLY AND CO | Transdermal delivery rate control using amorphous pharmaceutical compositions |
Jul, 2023
(2 months ago) | |
| US8993520 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Jun, 2026
(2 years from now) | |
| US9180194 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Jun, 2026
(2 years from now) | |
| US8807861 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(3 years from now) | |
| US8419307 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(3 years from now) | |
| US9289586 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(3 years from now) | |
| US8435944 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Sep, 2027
(3 years from now) | |
Axiron is owned by Eli Lilly And Co.
Axiron contains Testosterone.
Axiron has a total of 7 drug patents out of which 1 drug patent has expired.
Expired drug patents of Axiron are:
- US8784878
Axiron was authorised for market use on 23 November, 2010.
Axiron is available in solution, metered;transdermal dosage forms.
Axiron can be used as a method of transdermally delivering testosterone, a method of increasing the testosterone blood level of a person in need thereof, a method of increasing the testosterone blood level of an adult male subject in need thereof, a method of transdermal administration of a physiologically active agent to a subject..
The generics of Axiron are possible to be released after 27 September, 2027.
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 23 November, 2010
Treatment: A method of transdermally delivering testosterone; A method of increasing the testosterone blood level of an adult male subject in need thereof; A method of transdermal administration of a physiologic...
Dosage: SOLUTION, METERED;TRANSDERMAL
AXIRON family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic